ArticleJournal of endocrinological investigation2026
Global prevalence of genetic carriers for ARMC5- and KDM1A-associated primary bilateral macronodular adrenal hyperplasia: insights from a large multiethnic genomic database.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo estimate the global prevalence of genetic carriers of primary bilateral macronodular adrenal hyperplasia (PBMAH)-associated variants in ARMC5 and KDM1A using a large genomic database.
methodsWe analyzed sequencing data from 807,162 unrelated individuals in gnomAD v4.1. Two prespecified variant-selection strategies were applied. Strict criteria included ARMC5 and KDM1A variants classified as pathogenic/likely pathogenic (P/LP) in ClinVar/LOVD and germline P/LP variants reported in the literature. Liberal criteria included all strict variants plus rare predicted deleterious variants (nonsense, frameshift, loss of start codon and splice-disrupting variants predicted to be deleterious by in silico analysis) and PBMAH-reported somatic ARMC5 variants from the literature as candidate germline susceptibility alleles. Carrier prevalence was estimated by aggregating allele frequencies of qualifying variants overall and by ancestry.
resultsFor ARMC5, estimated carrier prevalence was 37.5/100,000 under strict criteria and 64.1/100,000 under liberal criteria. Prevalence varied by ancestry, highest in East Asian individuals (strict: 111.4/100,000; liberal: 173.7/100,000) and lowest in Middle Eastern (strict: 0; liberal: 33.0/100,000) and Ashkenazi Jewish groups (strict: 6.8; liberal: 27.0/100,000). For KDM1A, only three variants met strict criteria; liberal criteria yielded an estimated carrier prevalence of 33.8/100,000, highest in Middle Eastern (66.0/100,000) and lowest in Finnish (6.2/100,000). Several variants were enriched in specific ancestries (e.g., ARMC5 p.Arg454Trp in East Asians; ARMC5 p.Arg879Trp and KDM1A p.Arg196AsnfsTer6 in non-Finnish Europeans).
conclusionPopulation-scale data suggest PBMAH genetic susceptibility due to ARMC5 and KDM1A variants may be more common than implied by clinical series and differs across ancestries, underscoring the need for improved variant curation and phenotype-linked studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.